An experimental mRNA cancer vaccine developed with the help of artificial intelligence (AI) has shown promising results after successfully shrinking a ...
Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in ...
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...
The U.S. Food and Drug Administration will review a messenger RNA (mRNA) flu vaccine for approval, according to its maker, Moderna. The decision is a dramatic U-turn for the agency, which, only about ...
The U.S. Food and Drug Administration is refusing to review Moderna’s application for approval of an mRNA-based flu vaccine, the latest step taken by the administration that might affect the use of ...
The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.
Modern synthetic biology and AI represent both medicine’s greatest breakthrough and warfare’s most terrifying evolution. In this new landscape, where biological weapons can be designed faster than ...
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
The relative efficacy of a modified mRNA vaccine as compared with the standard inactivated vaccine against influenza-like illness was 34.5%, meeting noninferiority and superiority. Those who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results